CA 125 HE4 ROMA Index Calculator
Use this premium ROMA calculator to estimate the Risk of Ovarian Malignancy Algorithm percentage from CA 125, HE4, and menopausal status. Enter laboratory values, calculate instantly, and review a visual chart plus an expert guide below.
Interactive ROMA Index Calculator
What the CA 125 HE4 ROMA Index Calculator Measures
The CA 125 HE4 ROMA index calculator is a clinical estimation tool used to combine two tumor marker values, CA 125 and HE4, with menopausal status to estimate the probability that an adnexal or pelvic mass is associated with epithelial ovarian malignancy. ROMA stands for Risk of Ovarian Malignancy Algorithm. Rather than relying on a single biomarker, the algorithm integrates multiple data points because ovarian cancer evaluation is often more accurate when markers are interpreted together instead of in isolation.
CA 125 is one of the best known blood markers in gynecologic oncology. It may be elevated in ovarian cancer, but it can also rise in benign conditions such as endometriosis, menstruation, pelvic inflammatory disease, pregnancy, and liver disease. HE4, or human epididymis protein 4, is another biomarker that tends to be less frequently elevated in some benign gynecologic conditions. The ROMA approach was designed to improve risk stratification by mathematically combining these markers and applying different coefficients for premenopausal and postmenopausal patients.
This calculator is meant for educational and informational use. It is not a diagnosis, and it should never replace clinician judgment, ultrasound findings, pathology review, or specialist referral. Laboratory methods also vary, and real-world interpretation always depends on the assay used, the patient’s age, renal function, symptoms, imaging results, and the overall clinical setting.
How the ROMA Formula Works
The ROMA score is based on a predictive index, often abbreviated as PI. The formula differs by menopausal status:
Premenopausal formula
- PI = -12.0 + 2.38 × ln(HE4) + 0.0626 × ln(CA 125)
- ROMA % = exp(PI) ÷ (1 + exp(PI)) × 100
Postmenopausal formula
- PI = -8.09 + 1.04 × ln(HE4) + 0.732 × ln(CA 125)
- ROMA % = exp(PI) ÷ (1 + exp(PI)) × 100
The natural logarithm function means the algorithm does not respond to biomarker increases in a simple linear way. For example, doubling a value does not literally double the ROMA percentage. That is one reason calculator-based interpretation is useful. Small and large changes in CA 125 or HE4 may influence risk differently depending on the baseline values and the menopausal category chosen.
Common interpretive cut points
Many references cite the following commonly used thresholds, though exact values can vary by assay and laboratory validation:
- Premenopausal: ROMA 11.4% or higher may be classified as high risk.
- Postmenopausal: ROMA 29.9% or higher may be classified as high risk.
These thresholds help clinicians identify patients who may benefit from referral to a gynecologic oncologist, especially when imaging or symptoms raise concern. Still, no blood test should be interpreted outside context. Normal values do not eliminate cancer, and elevated values do not prove cancer.
Why CA 125 and HE4 Are Combined
CA 125 alone has long been used in ovarian cancer evaluation, but it has well-recognized limitations. Premenopausal patients may have elevated CA 125 because of benign conditions, so specificity can be reduced. HE4 may add discriminatory power because it is often less influenced by certain benign gynecologic causes. By combining both markers with menopausal status, the ROMA index attempts to balance sensitivity and specificity more effectively than using either biomarker on its own.
That said, biomarker algorithms are still imperfect. Renal impairment can elevate HE4. Different histologic subtypes of ovarian malignancy may behave differently. Mucinous tumors, early-stage disease, and non-epithelial neoplasms may not follow the same biomarker patterns seen in advanced high-grade serous carcinoma. For that reason, ROMA should be viewed as one piece of a broader diagnostic pathway.
Step-by-Step Guide to Using This Calculator
- Enter the measured CA 125 value from the laboratory report.
- Enter the measured HE4 value from the laboratory report.
- Select premenopausal or postmenopausal status.
- Click Calculate ROMA Index.
- Review the displayed predictive index, ROMA percentage, and the low-risk or high-risk classification.
- Use the chart to visualize how CA 125, HE4, and ROMA compare on a normalized scale.
If your laboratory report uses unusual units, confirm unit compatibility before interpretation. The formulas applied here are typically used with CA 125 in U/mL and HE4 in pmol/L. If your report differs, ask the laboratory or ordering clinician whether conversion is needed.
Clinical Context Matters More Than a Single Number
One of the biggest mistakes in biomarker interpretation is treating a single threshold as absolute proof. In practice, the most informative clinical assessment usually includes:
- Pelvic ultrasound findings such as solid components, papillary projections, septations, vascularity, and ascites
- Symptoms such as bloating, early satiety, pelvic pressure, abdominal pain, or urinary urgency
- Family history of ovarian, breast, pancreatic, or colorectal cancer
- Age and menopausal status
- Renal function, which can affect HE4
- Trend over time rather than only one biomarker snapshot
When a patient has a suspicious adnexal mass, specialist triage can affect outcomes because surgery performed by gynecologic oncologists is associated with better staging and treatment planning in ovarian malignancy. That is one reason risk tools like ROMA exist: not to replace imaging or pathology, but to support better referral decisions.
Population Statistics Relevant to Ovarian Cancer Risk Assessment
To understand where ROMA fits, it helps to look at broad ovarian cancer statistics from major U.S. sources. Ovarian cancer is less common than some other cancers, but it remains clinically important because it is often diagnosed at a later stage.
| U.S. Ovarian Cancer Statistic | Approximate Value | Why It Matters |
|---|---|---|
| Estimated new ovarian cancer cases in 2024 | 19,680 | Shows the annual burden of disease in the United States. |
| Estimated ovarian cancer deaths in 2024 | 12,740 | Highlights the seriousness of delayed diagnosis and advanced-stage presentation. |
| Approximate 5-year relative survival, all stages combined | About 50% | Survival improves when disease is identified and managed appropriately. |
| Median age at diagnosis | About 63 years | Explains why menopausal status is clinically relevant in risk algorithms. |
These numbers are broadly consistent with data summarized by the National Cancer Institute and related U.S. government cancer surveillance resources. The key takeaway is not simply that ovarian cancer is dangerous, but that risk stratification and referral matter. A calculator like ROMA is not a screening shortcut for healthy people. Instead, it is most meaningful when a patient already has findings that warrant further evaluation.
Reference Thresholds and Practical Interpretation
| Measure | Common Reference Point | Clinical Caution |
|---|---|---|
| CA 125 | Often 35 U/mL used as an upper reference threshold | May be elevated in many benign conditions, especially before menopause. |
| HE4 | Reference intervals vary by assay and menopause status | Can rise with reduced kidney function and assay-specific factors. |
| ROMA, premenopausal | High risk often defined as 11.4% or greater | Use only with appropriate assay validation and full clinical context. |
| ROMA, postmenopausal | High risk often defined as 29.9% or greater | Thresholds may differ by laboratory platform and manufacturer guidance. |
When the ROMA Score May Be Most Helpful
1. Evaluating an adnexal mass
The most common role for ROMA is in the workup of an ovarian or adnexal mass that has already been identified clinically or by imaging. In that setting, the score can contribute to the decision about whether management should include specialist referral.
2. Supporting surgical planning
If preoperative concern for malignancy is high, referral to a gynecologic oncology team may improve initial management, staging, and debulking decisions. Biomarker risk estimation may support this pathway.
3. Clarifying mixed biomarker patterns
Sometimes CA 125 is only mildly elevated while HE4 is more clearly abnormal, or vice versa. The algorithm helps integrate both values in a mathematically consistent way rather than relying on intuition alone.
Limitations of the CA 125 HE4 ROMA Index Calculator
- It is not a screening test for asymptomatic average-risk individuals.
- It does not diagnose ovarian cancer.
- It may be less reliable in certain tumor subtypes or clinical scenarios.
- HE4 can be affected by renal impairment and possibly age-related factors.
- Different assay platforms may use different validation thresholds.
- It should not overrule suspicious imaging, symptoms, or clinician concern.
These limitations are essential. A reassuring ROMA result does not eliminate the need for follow-up if imaging is worrisome. Likewise, a high-risk ROMA result does not automatically mean cancer is present. False positives and false negatives both occur, which is why multidisciplinary interpretation remains best practice.
Frequently Asked Questions
Is a higher ROMA percentage always worse?
In general, a higher percentage indicates a higher estimated risk category within the algorithm, but it is not a direct measure of cancer stage, tumor size, or prognosis. It is a triage tool, not a pathology report.
Can normal CA 125 still occur in ovarian cancer?
Yes. Some ovarian cancers do not produce major CA 125 elevations, especially in earlier stages or certain histologic subtypes. That is one reason why CA 125 alone is not sufficient.
Why do menopause-specific formulas matter?
Background biomarker behavior differs between premenopausal and postmenopausal populations. The ROMA model uses different coefficients to account for these differences and improve risk classification.
Should patients use ROMA for self-diagnosis?
No. The score is best interpreted by a clinician who can consider imaging, symptoms, medical history, and laboratory method details. Self-interpretation without context may cause unnecessary alarm or false reassurance.
Authoritative Sources for Further Reading
- National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- MedlinePlus: CA 125 Test
- National Library of Medicine Bookshelf and clinical references
Bottom Line
The CA 125 HE4 ROMA index calculator is a useful decision-support tool for estimating risk in patients being evaluated for an adnexal mass. It combines CA 125, HE4, and menopausal status into a single percentage that can help classify risk and guide referral decisions. Its value lies in structured interpretation, not certainty. The best use of ROMA is alongside imaging, history, examination, and specialist judgment.